Seamus Mulligan bought $10.0M of Jazz Pharmaceuticals (JAZZ)
Executed May 9 2025, disclosed May 13 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (May 13 2025), the stock returned +6.9% (delay-adjusted); from the execution session (May 9 2025), +13.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
Seamus Mulligan (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Jazz Pharmaceuticals plc (JAZZ). Across 1 priced purchase filing, the average 21-session return was +13.4% from execution and +6.9% from disclosure (delay-adjusted; derived). The largest single filing was $10.0M of JAZZ (101,521 sh across 3 lots, as filed), executed May 9 2025.
Healthcare · Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→